How Has The Mycoplasma Testing Market Size Evolved In Recent Years?
The mycoplasma testing market has seen considerable growth due to a variety of factors.
• The market size for mycoplasma testing has seen rapid expansion in the past few years. It's projected to escalate from $1.08 billion in 2024 to $1.23 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.7%.
This growth in the historic term is due to outbreaks and contamination incidents, heightened awareness, growth in the biotechnology sector, research and development efforts, trends in the healthcare industry, and the hike in cell culture production.
What Is The Projected Growth And Market Size For The Mycoplasma Testing
The mycoplasma testing market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipations show that the mycoplasma testing market is set to witness significant expansion in the coming years, with predictions reaching $1.92 billion in 2029, demonstrating a Compound Annual Growth Rate (CAGR) of 11.7%.
Factors contributing to this projected growth over this period include an increased need for quality assurance, emergence of new markets, development of the biopharmaceutical industry, progress in cell-based therapies, and ongoing growth in the biotechnology sector. Furthermore, trends observed in the forecast period encompass adherence to regulatory standards, growing awareness in healthcare and diagnostics, preparedness for global pandemics, innovations in point-of-care testing, and deeper penetration into emerging markets.
What Main Forces Are Fueling Expansion In The Mycoplasma Testing Market?
The rise in instances of mycoplasma pneumonia is anticipated to fuel the expansion of the mycoplasma testing market. Mycoplasma pneumonia is a respiratory infection brought about by the Mycoplasma pneumoniae bacteria. The role of mycoplasma testing is critical in identifying this disease, as it detects the presence of Mycoplasma pneumoniae bacteria in respiratory samples, facilitating the prompt and accurate detection needed for suitable medical intervention and management. For example, in December 2023, the Centers for Disease Control and Prevention, a US government agency, estimated that there are around 2 million cases of Mycoplasma pneumoniae infections annually in the United States. Hence, the growing occurrence of mycoplasma pneumonia is pushing the mycoplasma testing market's growth forward.
What Are The Main Segments Of The Global Mycoplasma Testing Market?
The mycoplasma testing market covered in this report is segmented –
1) By Product: Instruments, Assay, Kits, and Reagents
2) By Technology: PCR, ELISA, Enzymatic Methods, DNA Staining, Other Technologies
3) By Application: Cell line Testing, Virus Testing, End- of- Production Cell Testing
4) By End User: Pharmaceutical & Biotechnology Companies, Cell Banks & Laboratories, Contract Research Organizations, Academic Research Institutes
Subsegments:
1) By Instruments: Mycoplasma Detection Systems, Automated Test Equipment, PCR Equipment
2) By Assay: Mycoplasma Assays (PCR-Based, Culture-Based), Qualitative Assays, Quantitative Assays
3) By Kits: Mycoplasma Detection Kits, Mycoplasma Testing Kits for Cell Cultures, Sample Preparation Kits
4) By Reagents: Nucleic Acid Reagents, Cell Culture Reagents, Staining Reagents
Pre-Book The Mycoplasma Testing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Mycoplasma Testing Market?
Key players in the mycoplasma testing market are driving growth through strategic initiatives such as launching novel products, pushing research and development frontiers, and technological innovation, gaining significant traction. To cater to the needs of end-users and broaden the customer base in a fiercely competitive landscape, businesses are bringing novel products to market. For instance, SwiftDx, a biotechnology firm in the UK, rolled out a new test for mycoplasma contamination in October 2022, employing a PCR-based technique. SwiftDx's Mycoplasma Detection Kit is a lateral flow test that presents a fast and accurate means of identifying mycoplasma using a small sampling straight from the cell culture media supernatant without hampering cell growth. It showcases results in a straightforward, easily interpretable manner. The test boasts high sensitivity and specificity, with a detection threshold below 10 cfu/mL post the third day of culture.
Who Are the Key Players in the Mycoplasma Testing Market?
Major companies operating in the mycoplasma testing market include:
• Abbott Laboratories
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Agilent Technologies Inc.
• Lonza Group AG
• Roche Diagnostics International AG
• Charles River Laboratories International Inc.
• Nelson Laboratories Fairfield Inc.
• Creative Bioarray
• Biological Industries Israel Beit Haemek Ltd.
• Biotools B & M Labs S.A
• PromoCell GmbH
• American Type Culture Collection
• Bionique Testing Laboratories Inc.
• InvivoGen
• Clongen Laboratories LLC
• Norgen Biotek Corporation
• Gen Bio Sciences (P) Ltd.
• GeneCopoeia Inc.
• Minerva Biolabs GmbH
• Mycoplasma Experience
• Savyon Diagnostics
• ScienCell Research Laboratories Inc.
What Is The Most Dominant Region In The Mycoplasma Testing Market?
North America was the largest region in the mycoplasma testing market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the mycoplasma testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
